HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Puts Price Tag On False COVID-19 Claims

First Amendment No License For Health Care Providers To Make False Claims

Executive Summary

Until coronavirus public health emergency ends, FTC is authorized to order civil penalties of $43,792 per violation found in COVID-19-related advertising. Health care providers, meanwhile, advertising to treat COVID-19 might be unfamiliar with 

You may also be interested in...



Conservative-Backed Group Mitigates Penalties In False COVID-19 Claims Settlement With FTC

Precision Patient Outcomes' compliance costs from settlement with FTC “are not onerous,” says New Civil Liberties Alliance attorney John Vecchione. Settlement requires firm to notify customers and resellers about lawsuit and preserve all scientific evidence for health claims made for its products.

The FTC Complaint Is Fully Visible. The COVID-19 'Mask' Is Not.

New York business partners continued false advertising for “The 1 Virus Buster Card,” to be worn around the neck or clipped onto clothing, on their website and social media platforms after receiving a warning from the US FTC in July 2020.

FTC Complaint Fully Visible Unlike COVID-19 'Mask'

New York business partners continued false advertising for “The 1 Virus Buster Card,” to be worn around the neck or clipped onto clothing, on their website and social media platforms after receiving a warning from in July 2020.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel